<DOC>
	<DOCNO>NCT02435173</DOCNO>
	<brief_summary>This study design explore CDZ173 , selective PI3Kδ inhibitor , patient genetically activate PI3Kδ , i.e. , patient APDS/PASLI . The study consist two part . Part I open label part design establish safety pharmacokinetics CDZ173 target population , well select optimal dose test part II . Part II design assess efficacy safety CDZ173 population .</brief_summary>
	<brief_title>Study Efficacy CDZ173 Patients With APDS/PASLI</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>patient document APDS/PASLIassociated genetic PI3K delta mutation study patient must nodal and/or extranodal lymphoproliferation correspond clinical finding manifestation compatible APDS/PASLI history repeat otosinopulmonary infection and/or organ dysfunction ( e.g. , lung , liver ) . Any medically significant disease condition unrelated APDS/PASLI Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>APDS ; PASLI ; PI3Kdelta</keyword>
</DOC>